Nycomed fights pantoprazole loss to post growth
This article was originally published in Scrip
Executive Summary
Nycomed's third-quarter net turnover crept up by almost 1% to €820 million despite losing patent exclusivity for its biggest selling product, pantoprazole (Protonix). Gross profits were also up, rising by 1% to €597 million.